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News and Events          July 2012 
From the University of Massachusetts Center for Clinical & Translational Science 
 
Discovering New Therapeutic Uses for Existing Molecules 
 
NCATS has recently announced a new pilot program to explore new therapeutic uses for existing 
molecules.  Eight participating companies have provided their compounds and related data, which were 
determined by the NIH to meet specific eligibility criteria.  For example, each compound must have 
advanced to clinical studies but been unsuccessful in its original therapeutic indication or not pursued 
for business reasons.  Preliminary information about the 58 compounds, including mechanism of 
action, route of administration, and any limitations in use based on safety and tolerability, are available 
at:  http://ncats.nih.gov/therapeutics-directory.html.  Researchers who are interested in NCATS’ 
Therapeutics Discovery funding must submit a pre-application in response to the NIH Funding 
Opportunity Announcement at:  http://grants.nih.gov/grants/guide/pa-files/PAR-12-203.html by August 
14, 2012.   
 
Investigators interested in applying for this program should contact Nate Hafer at 
nathaniel.hafer@umassmed.edu or 508-856-2511 for complete details. 
Lecture Series on Health Services Research Methods 
 
The first lecture, “Outcomes Assessment”, will be presented by John E. Ware, PhD on Wednesday, 
July 11, 1:00-2:30 PM, Hancock Hill Conference Room (AC7-050), ACC Building, UMass-
Worcester.  Lectures continue on Wednesdays and Thursdays throughout July and August.  For more 
information or questions, please call Ms. Kristie Capurso at 508-856-8821.  Sponsored by the Center 
for Outcomes Research, the Surgical Research Scholars Program, and the Department of Quantitative 
Health Sciences. 
 
Medical Device Design and Business Development for Entrepreneurs 
August 6-10, 2012 
Massachusetts Medical Device and Development Center (M2D2) 
600 Suffolk St, 2nd floor, Lowell 
To register and get more information click here  
 
The purpose of this course is to provide aspiring entrepreneurs with a valuable toolbox of concepts and 
networks for advancing their medical device design and development processes.  Topics include needs 
finding, needs screening, concept generation, intellectual property basics, regulatory affairs basics, 
reimbursement basics, business models, prototyping, and final concept selection. 
Shaping Our World-SHOW:  Beyond Treading Water: Functional Analysis of Tumor Initiation 
and Maintenance 
 
When: Thursday, July 26, 2012 from 6:00 pm - 9:00 pm 
Where: Harvard Institutes of Medicine, Bray Room - First Floor, Blackfan Circle – 4, Boston, MA 
 
Learn more and register on the Event webpage.  Attendance is free but pre-registration is required. 
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July's SHOW will focus on the genetic pathways that drive the development of cancer.  Specifically, we 
will look at melanoma, an aggressive form of skin cancer, which has been on the rise of late.  Though 
making up only five percent of skin cancer cases, melanoma is responsible for a large number of the 
deaths associated with skin cancers, having a particularly poor prognosis when diagnosed in its later 
stages.  Our special guest speaker, Dr. Craig J. Ceol, Assistant Professor of Molecular Medicine at 
the University of Massachusetts Medical School, has been working to identify the genetic defects 
responsible for the growth of tumors, specifically malignant melanoma. 
 
Fifth Annual CTSA Consortium Community Engagement Conference 
Methods, Metrics and Outcomes: Evaluating the Success of Community Engaged Research 
August 23 – 24, 2012 
Bethesda North Marriott Hotel & Conference Center 
Bethesda, MD 
 
Conference goals are to demonstrate feasible and replicable methods and metrics developed by and 
with communities that have improved individual and community health, particularly within underserved 
communities; facilitate the application of these methodologies and metrics to diverse local settings; and 
share tools for assessing and improving the effectiveness of community engagement in improving 
individual and community health outcomes.
Institutional CTSA Funding Opportunity Announced 
 
NCATS released the long-anticipated new funding announcement for institutional CTSAs on Friday, 
July 6.  More information is available here.  The UMCCTS plans to re-compete for additional funding 
in 2014, near the end of our current funding period. 
 
New Funding Round for Therapeutics for Rare and Neglected Diseases (TRND) Program 
Read full announcement here 
 
The NCATS Therapeutics for Rare and Neglected Diseases (TRND) program performs preclinical 
and early clinical development of new drugs for rare and neglected diseases, and develops new 
technologies and paradigms to improve the efficiency of therapeutic development for these 
diseases.  The TRND program will partner with academic laboratories, not-for-profit organizations, and 
for-profit companies.  Successful applicants will collaborate with TRND to create and implement a 
therapeutic development project plan.  Note:  This is not a grant or contract program; no extramural 
funding will be provided. 
 
For more information about the TRND program, including deadlines for current or upcoming 
opportunities, please visit the TRND webpage at http://trnd.nih.gov. 
 
3rd Conference on Clinical Research for Rare Diseases 
 
The Rare Diseases Clinical Research Network (RDCRN) and the Clinical and Translational Science 
Awards (CTSA) are sponsoring the 3rd Conference on Clinical Research for Rare Diseases (CCRRD) 
on Tuesday October 2, 2012 in Rockville, Maryland.  This unique conference will focus on research 
methodology for rare diseases and should be of particular interest to trainees and junior faculty 
engaged in research in rare diseases.  For more information about the conference, including details 
about the program, applying for travel awards, and conference logistics and registration, visit the 
conference website: https://rarediseasesnetwork.epi.usf.edu/conference/ 
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CVIP UMass Startup Initiative 
 
The Office of Commercial Ventures and Intellectual Property (CVIP) in the President’s Office has 
instituted the UMass Startup Initiative (UMSI) to foster the creation of startups at UMass.  This program 
augments other funding initiatives which currently include the CVIP Technology Development Award 
and the UMass Co-Investment Equity Fund.  The UMSI will make five thousand dollar ($5,000) 
grants available to the UMass campuses to prepare business plans that address the commercial 
potential of inventions disclosed to CVIP.  The business plan will be prepared by an external 
consultant with relevant commercial experience working closely with the key investigator of the 
disclosed invention.  CVIP will assist with the selection of the consultant.  The business plans will be 
used by CVIP to determine the feasibility of a startup and after that determination CVIP will assist in 
seeking management and then investment for the new companies.  Initially the awards will be available 
on a request basis.  All applicants will be asked to submit a brief application describing the technology, 
its commercial application and the rationale for creating a startup.  Selection of the awardees will be 
made by CVIP with the assistance of an external advisory group. 
 
For full details and application instructions, please contact: Dr. Bill Rosenberg, Executive Director 
CVIP at wrosenberg@umassp.edu or Nate Hafer at nathaniel.hafer@umassmed.edu .
 
Please remember to cite the UMCCTS grant UL1RR031982 and UL1TR000161 in all journal 
publications. 
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